Innovative Medicines Initiative (IMI) Case Study Analysis Reveals the True Added Value of Early-Phase Public-Private Partnerships (PPPs). - National Genomics Data Center (CNCB-NGDC)

Advanced Search

Innovative Medicines Initiative (IMI) Case Study Analysis Reveals the True Added Value of Early-Phase Public-Private Partnerships (PPPs).

Hilde Stevens, Geertrui Van Overwalle, Bart Van Looy, Isabelle Huys

Author Information

PMID: 26396462 DOI: 10.1089/blr.2015.29008.hs

No abstract text available.

Journal Article

The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.Workshop on public health law and ethics I & II: The challenge of public/private partnerships (PPPs).[The Innovative Medicine Initiative (IMI)].Public-private partnerships as driving forces in the quest for innovative medicines.Can public-private partnerships (PPPs) improve the environmental performance of urban sewage treatment?[Public-private partnerships (PPPs) in the health sector: global processes and national dynamics].The innovative medicines initiative: a public private partnership model to foster drug discovery.Editorial: Impacts of public-private collaborative research on Alzheimer's disease: the case of the innovative medicines initiative.The innovative medicines initiative (IMI): a shot in the arm for European diabetes research?The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project.

Intellectual property policies in early-phase research in public-private partnerships.Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review.Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.